Skip to content
10-Q

Quarterly Report

LUMOS PHARMA, INC.

0001126234-24-000062

← back to feed
Filed
May 15, 2024 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2024 · May 10, 2024 8.12M sh
Shares Diluted Q1 2024 · Mar 31, 2024 8.1M sh
Shares Diluted Q1 2024 · Mar 31, 2023 8.24M sh
Stock Repurchased Q1 2024 · Mar 31, 2024 $0
Stock Repurchased Q1 2024 · Mar 31, 2023 $305K
Operating Cash Flow Q1 2024 · Mar 31, 2024 −$12.89M
Operating Cash Flow Q1 2024 · Mar 31, 2023 −$9.2M
Short Term Investments Q1 2024 · Mar 31, 2024 $0
Short Term Investments Q1 2024 · Dec 31, 2023 $999K
Cash And Equivalents Q1 2024 · Mar 31, 2024 $23.18M
Cash And Equivalents Q1 2024 · Dec 31, 2023 $35.08M
Stockholders Equity Q1 2024 · Mar 31, 2024 $17.44M
Stockholders Equity Q1 2024 · Dec 31, 2023 $27.31M
Stockholders Equity Q1 2024 · Mar 31, 2023 $52.52M
Stockholders Equity Q1 2024 · Dec 31, 2022 $59.58M
Current Liabilities Q1 2024 · Mar 31, 2024 $4.41M
Current Liabilities Q1 2024 · Dec 31, 2023 $7.03M
Total Liabilities Q1 2024 · Mar 31, 2024 $10.64M
Total Liabilities Q1 2024 · Dec 31, 2023 $13.33M
Current Assets Q1 2024 · Mar 31, 2024 $27.54M
Current Assets Q1 2024 · Dec 31, 2023 $40.04M
Total Assets Q1 2024 · Mar 31, 2024 $28.08M
Total Assets Q1 2024 · Dec 31, 2023 $40.64M
Eps Diluted Q1 2024 · Mar 31, 2024 −$1.29
Eps Diluted Q1 2024 · Mar 31, 2023 −$0.89
Eps Basic Q1 2024 · Mar 31, 2024 −$1.29
Eps Basic Q1 2024 · Mar 31, 2023 −$0.89
Sga Expense Q1 2024 · Mar 31, 2024 $3.78M
Sga Expense Q1 2024 · Mar 31, 2023 $4.36M
Rd Expense Q1 2024 · Mar 31, 2024 $7.25M
Rd Expense Q1 2024 · Mar 31, 2023 $4.37M
Net Income Q1 2024 · Mar 31, 2024 −$10.44M
Net Income Q1 2024 · Mar 31, 2023 −$7.35M
Operating Income Q1 2024 · Mar 31, 2024 −$10.86M
Operating Income Q1 2024 · Mar 31, 2023 −$8.04M
Revenue Q1 2024 · Mar 31, 2024 $165K
Revenue Q1 2024 · Mar 31, 2023 $691K